1,236 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Breed s Hill Capital LLC

Breed s Hill Capital LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 1,236 shares of the pharmaceutical company’s stock, valued at approximately $498,000.

Other institutional investors also recently modified their holdings of the company. ABC Arbitrage SA bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth about $1,510,000. Highview Capital Management LLC DE increased its stake in shares of Vertex Pharmaceuticals by 1.8% in the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company’s stock worth $2,324,000 after acquiring an additional 102 shares in the last quarter. Davidson Investment Advisors increased its stake in shares of Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company’s stock worth $24,630,000 after acquiring an additional 12,631 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Vertex Pharmaceuticals by 75.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company’s stock worth $994,000 after acquiring an additional 1,062 shares in the last quarter. Finally, Concord Wealth Partners increased its stake in shares of Vertex Pharmaceuticals by 32.6% in the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock worth $1,413,000 after acquiring an additional 862 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $434.03 on Friday. The company has a 50 day moving average price of $477.78 and a 200-day moving average price of $463.56. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a market capitalization of $111.46 billion, a PE ratio of -197.29, a P/E/G ratio of 2.11 and a beta of 0.51. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $4.76 earnings per share. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VRTX. JPMorgan Chase & Co. increased their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 6th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. The Goldman Sachs Group restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Piper Sandler reduced their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Bank of America raised their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Thirteen investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $515.04.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 530 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company’s stock, valued at $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,813 shares of company stock worth $1,889,514. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.